Literature DB >> 8195578

Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects.

C Geretsegger1, F Böhmer, M Ludwig.   

Abstract

The efficacy of paroxetine and fluoxetine and their effects on cognitive and behavioural function were compared in a 6 week, double-blind, randomized study of 106 elderly depressed patients (aged 61 to 85 years). Antidepressant efficacy was assessed using the Hamilton depression rating scale (HAMD), Montgomery-Asberg Depression Rating Scale (MADRS) and Clinical Global Impression (CGI) scale. The Sandoz Clinical Assessment Geriatric scale (SCAG), the Mini-Mental State Examination (MMSE), and HAMD cognitive factor scores were used to assess cognitive and behavioural function. Paroxetine demonstrated comparable efficacy to fluoxetine in the treatment of elderly depressed patients, but at the end of treatment, there was a significantly higher proportion of responders to paroxetine than to fluoxetine. Both treatments produced improvements in all measures of cognitive and behavioural function, but paroxetine was significantly superior to fluoxetine from Week 3, indicating a possible early effect. There was no difference between the two agents in either the tolerability or safety of treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8195578

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  12 in total

Review 1.  Pharmacologic treatment of depression in late life.

Authors:  A J Flint
Journal:  CMAJ       Date:  1997-10-15       Impact factor: 8.262

Review 2.  Drug-induced cognition disorders in the elderly: incidence, prevention and management.

Authors:  S L Gray; K V Lai; E B Larson
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

Review 3.  Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.

Authors:  Ai Leng Khoo; Hui Jun Zhou; Monica Teng; Liang Lin; Ying Jiao Zhao; Lay Beng Soh; Yee Ming Mok; Boon Peng Lim; Kok Peng Gwee
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

Review 4.  Paroxetine. A pharmacoeconomic evaluation of its use in depression.

Authors:  M I Wilde; R Whittington
Journal:  Pharmacoeconomics       Date:  1995-07       Impact factor: 4.981

Review 5.  Fluoxetine. A pharmacoeconomic review of its use in depression.

Authors:  M I Wilde; P Benfield
Journal:  Pharmacoeconomics       Date:  1998-05       Impact factor: 4.981

6.  Systematic review and guide to selection of selective serotonin reuptake inhibitors.

Authors:  J G Edwards; I Anderson
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

Review 7.  Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness.

Authors:  M G Harris; P Benfield
Journal:  Drugs Aging       Date:  1995-01       Impact factor: 3.923

Review 8.  Choosing appropriate antidepressant therapy in the elderly. A risk-benefit assessment of available agents.

Authors:  A J Flint
Journal:  Drugs Aging       Date:  1998-10       Impact factor: 3.923

9.  Cognitive performance in depressed patients after chronic use of antidepressants.

Authors:  Clarice Gorenstein; Stefania Caldeira de Carvalho; Rinaldo Artes; Ricardo Alberto Moreno; Tania Marcourakis
Journal:  Psychopharmacology (Berl)       Date:  2006-02-17       Impact factor: 4.530

10.  Multicenter double blind study of paroxetine and amitriptyline in elderly depressed inpatients.

Authors:  C Geretsegger; C H Stuppaeck; M Mair; T Platz; R Fartacek; M Heim
Journal:  Psychopharmacology (Berl)       Date:  1995-06       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.